Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements

EJHaem Pub Date : 2025-05-08 DOI:10.1002/jha2.70047

Xi Cao, Carolyn Mulroney, Huan-You Wang

{"title":"Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements","authors":"Xi Cao, Carolyn Mulroney, Huan-You Wang","doi":"10.1002/jha2.70047","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Indolent T-cell lymphoma of the gastrointestinal tract (ITCL-GI) is a rare primary T-cell lymphoma from the gastrointestinal (GI) tract, there has been no documented successful treatment at the present time.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A CD4(+)/CD8(−) ITCL-GI with <i>STAT3::JAK2</i> fusion was treated with Jakafi (Ruxolitinib), which resulted in significant clinical improvements.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Next generation sequencing is highly recommended for any new diagnosis of CD4(+)/CD8(−) ITCL-GI in order to detect if <i>STAT3::JAK2</i> can be found in order to treat the patient with JAK2 inhibitor such as Jakafi (Ruxolitinib).</p>\n </section>\n \n <section>\n \n <h3> Clinical trial registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70047","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Indolent T-cell lymphoma of the gastrointestinal tract (ITCL-GI) is a rare primary T-cell lymphoma from the gastrointestinal (GI) tract, there has been no documented successful treatment at the present time.

Results

A CD4(+)/CD8(−) ITCL-GI with STAT3::JAK2 fusion was treated with Jakafi (Ruxolitinib), which resulted in significant clinical improvements.

Conclusion

Next generation sequencing is highly recommended for any new diagnosis of CD4(+)/CD8(−) ITCL-GI in order to detect if STAT3::JAK2 can be found in order to treat the patient with JAK2 inhibitor such as Jakafi (Ruxolitinib).

Clinical trial registration

The authors have confirmed clinical trial registration is not needed for this submission.

Abstract Image

查看原文本刊更多论文

Jakafi （Ruxolitinib）治疗含有STAT3::JAK2的胃肠道惰性t细胞淋巴瘤临床疗效显著

胃肠道惰性t细胞淋巴瘤（ITCL-GI）是一种罕见的胃肠道原发性t细胞淋巴瘤，目前尚未有成功治疗的文献记载。结果Jakafi （Ruxolitinib）治疗STAT3::JAK2融合的CD4(+)/CD8(−)ITCL-GI，临床效果明显改善。结论强烈建议对任何新的CD4(+)/CD8(−)ITCL-GI进行新一代测序，以检测STAT3::JAK2是否存在，以便治疗Jakafi （Ruxolitinib）等JAK2抑制剂患者。临床试验注册作者已确认该提交不需要临床试验注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量